Loading clinical trials...
Loading clinical trials...
Psychiatric Multi-omics and Neuroimaging Project Database
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.
The study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. So we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.
Age
13 - 35 years
Sex
ALL
Healthy Volunteers
Yes
The Second Xiangya hospital of central south univerity
Changsha, Hunan, China
Start Date
January 1, 2016
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2027
Last Updated
March 13, 2026
1,899
ESTIMATED participants
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
DRUG
Lead Sponsor
mingjun Zhong
NCT05508789
NCT06780917
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions